BofA raised the firm’s price target on Penumbra (PEN) to $370 from $320 and keeps a Buy rating on the shares as the firm moves the valuation year out one year to reflect the calendar change while highlighting its medtech picks for 2026.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PEN:
- Penumbra price target raised to $370 from $312 at Truist
- Penumbra: Accelerating Growth, Margin Upside, and 2026+ Catalysts Support Overweight (Buy) Rating
- Penumbra upgraded to Overweight from Neutral at JPMorgan
- Penumbra price target raised to $355 from $325 at RBC Capital
- Penumbra price target raised to $359 from $355 at Canaccord